Avineuro Project

Avineuro Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing novel small molecules for the treatment of central nervous system (CNS) disorders, including schizophrenia, anxiety, and cognitive dysfunction. A subsidiary of the ChemRar High-Tech Center, the company utilizes a rational drug discovery approach that integrates medicinal chemistry with streamlined clinical development. Its lead product, AVIANDR (maritupirdine), is a multi-target small molecule recently registered in Russia for generalized anxiety disorder. Other pipeline candidates include AVN-211 for schizophrenia and AVN-322 for cognitive disorders. Avineuro operates with headquarters in Hallandale Beach, Florida, and significant operations in Russia.